Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | STS | P08842 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175718 | 0.88 | SRC (0.39) | SRC | |
| SCHEMBL16362230 | 0.88 | ALDH1A1 (0.41) | SRC | |
| SCHEMBL2661317 | 0.84 | AR (0.38) | SRC | |
| SCHEMBL3841263 | 0.82 | HSD11B1 (0.31) | HSD11B1CXCR2 | |
| SCHEMBL5561363 | 0.82 | FFAR4 (0.37) | HSD11B1CXCR2 | |
| SCHEMBL6022698 | 0.81 | ALDH1A1 (0.46) | — | |
| SCHEMBL6022694 | 0.81 | ALDH1A1 (0.46) | — | |
| SCHEMBL13882856 | 0.81 | SRC (0.41) | SRC | |
| Iodide SCHEMBL20377402 | 0.80 | FFAR4 (0.36) | HSD11B1CXCR2 | |
| SCHEMBL147333 | 0.80 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9073864-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20150152052-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2832725-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-1863475-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007123581-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1758859-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006137019-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006100635-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005118542-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-5965763-A | Biphenyl compounds | HOECHST MARION ROUSSEL (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5827887-A | 5-ALPHA REDUCTASE INHIBITORS | ROUSSEL UCLAF (FR) | 1998-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152052-A1 | AROMATIC RING COMPOUND | GLP1R, GCGR, IAPP | SRC 3262/4885HSD11B1 689/4885STS 2158/4885 |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | SRC 3928/4885HSD11B1 227/4885STS 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.